MOTS-c + NAD-IV: The Mitochondrial Longevity Stack

What this stack does

MOTS-c is a peptide encoded in the mitochondrial genome that signals through AMPK and SIRT3, improving cellular energy metabolism and insulin sensitivity. NAD-IV (intravenous nicotinamide adenine dinucleotide) restores NAD+ pools, the critical cofactor for mitochondrial respiration, sirtuin activation, and DNA repair. NAD+ declines with age, particularly in men over 35, impairing both energy production and adaptive stress response.

Together, they address two complementary deficits: MOTS-c initiates the signalling cascade that cells use to upregulate mitochondrial function, while NAD-IV provides the substrate those pathways need to work. Research shows MOTS-c improves glucose metabolism in animal models and anecdotally users report sustained energy improvements within 3-4 weeks. NAD-IV provides more rapid sensory feedback (hours to days), but requires repeated dosing to maintain elevated NAD+ levels since the body metabolises it quickly.

The combination is often used in the recovery and longevity space by men returning from layoff or managing chronic metabolic stress (training, age-related decline, occupational demand). It is not a replacement for basic metabolic hygiene (sleep, training, nutrient intake), but a targeted enhancement when those fundamentals are already in place.

Who it's for

High-performing men 35+ who report sustained fatigue despite adequate sleep and training, or who have experienced a decline in work capacity or recovery speed over the past 2-3 years. This includes men returning from significant training layoff (injury, family commitment, professional overload) and those managing multiple stressors simultaneously (high-demand work, intense training, age-related metabolic shift).

The stack assumes baseline metabolic health: normal resting heart rate variability, no uncontrolled diabetes, no active cardiac arrhythmias. It is not a fix for poor sleep, caloric surplus, or sedentary behaviour. Users typically have a measurable goal: improved sustained energy, faster recovery from training, or objective biomarker improvement (fasting glucose, lactate clearance, VO2 max) over 12 weeks.

Men who value metabolic precision over short-term appearance changes, and who are willing to measure (blood work, training metrics, energy logs) rather than guess, typically see the clearest outcomes.

The protocol

MOTS-c: 10 mg subcutaneous injection once daily, typically in the morning or 30-60 minutes before training. Standard reconstitution is 10 mg per 2 mL bacteriostatic water (5 mg/mL stock). Draw and inject 0.2 mL (1 mg) per dose. Duration: 12 weeks on, 4 weeks off. Some users extend to 16 weeks on if baseline energy and biomarkers are tracking well; do not exceed 16 consecutive weeks without assessment.

NAD-IV: 500 mg intravenous infusion once weekly, typically Tuesday or Thursday to space evenly within the week. Infusion takes 15-30 minutes via peripheral IV or central line if available. Duration: 12 weeks, 500 mg weekly. Some practitioners extend to 750 mg weekly after 6 weeks if well-tolerated; this is optional and should be discussed with the administering clinician.

Timing and stacking: Begin NAD-IV first (week 1), then add MOTS-c in week 2 to isolate response to each compound. They do not interact directly and can be dosed concurrently after baseline is established. Take MOTS-c with or without food (food does not affect absorption of subQ peptides). NAD-IV should be given in a clinic or supervised setting; do not attempt to self-administer IV.

Cycle structure: 12 weeks on, 4 weeks complete off both compounds (no MOTS-c, no NAD-IV). This allows feedback on baseline metabolic state and prevents desensitisation. Repeat cycle 1-2 times per year depending on training phase and life stress.

Washout: MOTS-c clears in 24-48 hours. NAD+ returns to baseline within 2-4 days of final infusion. No special washout protocol required; simply stop dosing and resume normal routine.

What to expect, week by week

Week 1 (NAD-IV only): Mild cognitive lift 2-4 hours post-infusion. Some users report improved sleep quality (deeper, longer). No dramatic energy shift. Energy logs typically show minimal change.

Week 2 (MOTS-c added): Baseline established. No additional acute response expected yet.

Week 4: Most common timeline for users to report measurable sustained energy shift: less afternoon dip, faster recovery from training, slightly improved focus through mid-afternoon. Fasting glucose may begin to trend downward on labs (0.5-1.5 mg/dL drop is typical). Sleep may deepen further.

Week 8: Peak response window. Users often report near-complete restoration of energy baseline from 5+ years prior (if they entered at age 40-50). Lactate clearance and training tolerance typically improve. VO2 max may improve 3-5% on repeat testing. Blood work often shows improved glucose regulation, lower fasting insulin, improved lipid ratios in some users.

Week 12 (end of cycle): Sustained improvements. Energy stable. Some users report additional gains in training capacity in weeks 10-12.

Weeks 13-16 (off both): Energy and training metrics gradually soften. Most improvements persist at 70-80% through week 4 off. Baseline metabolic biomarkers typically remain improved 4-8 weeks post-cycle.

Side effects and safety

MOTS-c: Preclinical and early human data show minimal adverse effects. Injection site reactions (mild redness, tenderness) occur in <5% of users. Rare reports of transient headache or appetite suppression in first 1-2 weeks (typically mild and self-resolving). No serious adverse events reported in available literature, but human safety data remain limited.

NAD-IV: IV infusion can cause mild flushing, facial warmth, or transient nausea during or immediately post-infusion (usually resolved within 30 minutes). Risk of local thrombophlebitis if IV is placed poorly or left in situ too long. Headache or dizziness reported in <3% of users. IV-related infections (rare) require aseptic insertion technique and trained personnel.

Combined risk: No direct pharmacokinetic interaction. Both compounds work on distinct mitochondrial pathways and do not compete for clearance. However, users with baseline glucose dysregulation may see rapid improvements in insulin sensitivity; if on glucose-lowering medication, discuss with your clinician to avoid hypoglycaemia during the first 4-6 weeks.

Absolute contraindications: Active infection or fever (delay NAD-IV until resolved). Significant liver disease or renal impairment (both compounds are metabolised hepatically; check liver and kidney function before starting). Uncontrolled hypertension or active cardiac arrhythmias (NAD-IV can transiently raise blood pressure). Pregnancy or breastfeeding (data unavailable).

Compliance note: NAD-IV requires weekly clinical visits. MOTS-c requires self-injection skill and aseptic technique. Both are sourcing risks: NAD+ is relatively stable as a compound but degradation during storage or transport is possible; MOTS-c peptides are vulnerable to freeze-thaw cycles and contamination. Verify product quality with your supplier before use. Neither MOTS-c nor NAD-IV are prescription medications in most jurisdictions, but access via a qualified clinical team (ideally one trained in peptide and IV therapies) is strongly recommended for dose selection, monitoring, and complication management.

Sourcing and quality

MOTS-c: Sourced as lyophilised (freeze-dried) powder, typically 10 mg per vial. Verify that the vial is properly sealed, has no visible discoloration (should be white or off-white), and arrives with a Certificate of Analysis from a third-party lab (HPLC purity >95% is standard). Reconstitute with bacteriostatic water (0.9% sodium chloride with 0.9% benzyl alcohol), not saline or distilled water. Reconstituted solution is stable 2-3 weeks refrigerated (2-8°C); discard if cloudy, discolored, or past 3 weeks. Do not freeze reconstituted peptide.

NAD-IV: Sourced as pharmaceutical-grade NAD+ salt (usually nicotinamide adenine dinucleotide chloride or disodium form) in sterile vials. Verify batch-specific sterility and pyrogen testing documentation from your supplier. NAD+ is hygroscopic and degrades in humidity; storage should be in original sealed vials at 2-8°C. Do not expose to light. Vials should arrive with intact seals and no visible particulate matter. Your clinician will reconstitute in sterile saline immediately before infusion.

Use the reconstitution calculator to verify peptide concentration and inject volume for your dose if self-preparing MOTS-c stock solutions.

Frequently asked questions